Thursday, September 13

Thursday, September 13

2 – 3:15 pm

Opening Keynote: Never Ever Give Up! (101)

1CH  On March 3, 2011, eleven-year-old Jessie Rees, from Orange County, California, was diagnosed with an inoperable and incurable brain tumor (DIPG).

During her 10-month fight, Jessie wanted to spread joy to other kids fighting cancer and encourage them to Never Ever Give Up or “NEGU”- which was her personal motto of courage and strength. Jessie created JoyJars, 64-oz jars filled with toys and games, and would deliver them to kids in treatment as a way to encourage them to NEGU. She personally stuffed and sent over 3,000 of her JoyJars to kids across the United States.

Jessie’s mission continues today through the work of the Jessie Rees Foundation. To-date, the Jessie Rees Foundation has sent over 200,000 JoyJars to kids fighting cancer in all 50 states and in 33 countries.

Erik Rees
3:30 – 4:30 pm

Going Viral: Review of Viral Illness and Antiviral Therapy in Hematopoietic Stem Cell Transplant Pediatric Patients (200)

1CH  Hematopoietic stem cell transplant (HSCT) recipients are at significant risk for developing serious and sometimes fatal infectious complications. Common viral infections post-transplant occur from reactivation of a dormant virus, including herpes simplex (HSV), Varicella (VZV), cytomegalovirus (CMV), BK virus and Ebstein Barr Virus (EBV). Immunocompromised patients may also experience significant morbidity and mortality from common respiratory viruses, such as influenza, parainfluenza, adenovirus, and respiratory syncytial virus (RSV). Interventions vary greatly and can include prophylaxis, preemptive therapy or treatment of active infection. A variety of antiviral agents are now used including cellular immune therapy. A pharmacologic review will show that antiviral agents often have different dosage schemes, complex side effect profiles, and the need for supportive care.

3:30 – 4:30 pm

Introduction to Radiation Therapy: What Should a Nurse Know? (202)

1CH  Radiation therapy is an integral component of the overall management for many children with cancer. Better understanding of radiation therapy will improve the ability of nurses and advanced practice providers to care for these children. Review will include the underlying mechanisms of radiation in treating cancer and provide an overview of the common clinical indications for radiation. The presentation will provide an overview of the radiation planning and treatment process including dosing and fields using several case studies of children with different diagnoses. Common acute toxicities and management approach will be covered. Finally, common late effects and recommended follow-up care will be discussed.
3:30 – 4:30 pm

Putting the Horse before the CAR–T! Educating Nurses on Algorithms to Recognize Cytokine Release Syndrome and CAR–T Related Encephalopathy Syndrome (203)

1CH  Chimeric antigen receptor (CAR) therapies, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of hematologic malignancies in pediatric and adult populations, offer remarkable promise for patients with previously treated-refractory disease. Kymriah™, the first FDA-approved agent for the treatment of children and young adults up to 25 years of age with relapsed or refractory B–cell acute lymphoblastic leukemia, demonstrates an overall remission rates 83%. Significant, potentially life-threatening toxicities accompany these promising outcomes, most notably cytokine release syndrome (CRS) and CAR–related encephalopathy syndrome (CRES). Early identification and strategic management of symptoms are critical to support positive patient outcomes. An interprofessional team developed evidence-based algorithms for the diagnosis and management of CAR therapy-related toxicities.